RxDoctor Payments Data

Amy Gemperli, MD

Ophthalmology · Belton, MONPI 1336181718

Payments from drug & device makers

$3,439in general payments, 2019–2025

Across 93 payments — averaging $36.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$1K
  • Aerie Pharmaceuticals, Inc.$346
  • Rxsight Inc$101
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$94
  • Sight Sciences, Inc.$94
  • plus $420 from 12 others

What the payments were for

  • Food & beverage$3,423100%
  • Entertainment$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,439 in reported general payments places this provider in the 60th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$135,248
Medicare patients
464
Services billed
1,520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost104$56,465
RestasisCyclosporine28$32,252
RocklatanNetarsudil Mesylat/Latanoprost48$28,361
RhopressaNetarsudil Mesylate42$26,746
SimbrinzaBrinzolamide/Brimonidine Tart42$17,785
CombiganBrimonidine Tartrate/Timolol40$14,812
VyzultaLatanoprostene Bunod19$12,423
Latanoprost506$6,252
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol39$5,581
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat289$4,937
Dorzolamide-TimololDorzolamide/Timolol/Pf27$4,308
Travoprost29$3,612
Prednisolone Acetate76$3,094
Loteprednol Etabonate17$3,007
Acetazolamide18$1,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$1,267$103,529172 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$346$55,10790 claims
AlconSimbrinza$1,117$17,78542 claims
Bausch & Lomb Americas Inc.Vyzulta$90$12,42319 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$94$3,00717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Belton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →